| 000 | 01550 a2200217 4500 | ||
|---|---|---|---|
| 003 | OSt | ||
| 005 | 20251205111515.0 | ||
| 008 | 251205b |||||||| |||| 00| 0 eng d | ||
| 040 |
_aAIKTC-KRRC _cAIKTC-KRRC |
||
| 100 |
_aKameshwari, J. S. _927700 |
||
| 245 | _aCase report on toxic epidermal necrolysis with etoricoxib | ||
| 250 | _aVol.47(2), Mar-Apr | ||
| 260 |
_aMumbai _bWolter Kluwer _c2015 |
||
| 300 | _a221-223p. | ||
| 520 | _aEtoricoxib is a selective cyclo-oxygenase 2 (COX-2) enzyme inhibitor and is exploited for its analgesic activity in various disease conditions like osteoarthritis, gouty arthritis, acute pain including postoperative dental pain and primary dysmenorrhea, etc. Although highly efficacious in pain management the safety profile of this COX-2 inhibitor is yet to be established in a broader sense. Short-term clinical trials and postmarketing surveillance have shown a very rare incidence of very serious skin reactions like Steven Johnson syndrome or toxic epidermal necrolysis (TEN). In this case report, we summarize regarding a patient who developed TEN after treatment with etoricoxib for osteoarthritis that later resolved in 15 days after withdrawal and symptomatic treatment. | ||
| 650 | 0 |
_aPHARMACOLOGY _94774 |
|
| 700 |
_aDevde, Raju _927701 |
||
| 773 | 0 |
_tIndian Journal of Pharmacology _x0253-7613 _dAndheri - Mumbai Wolters Kluwer India Private Limited |
|
| 856 |
_uhttps://journals.lww.com/iphr/fulltext/2015/47020/a_case_report_on_toxic_epidermal_necrolysis_with.20.aspx _yClick here |
||
| 942 |
_2ddc _cAR |
||
| 999 |
_c23742 _d23742 |
||